Keenova Therapeutics plc has 11 Schedule 13D or 13G filings on record since 2025-08-04. 5 holders' latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| GoldenTree Asset Management LP | 20.2% | 7,926,176 | SCHEDULE 13D, 2025-08-07 | 2025-07-31 |
| Silver Point Capital, L.P. | 15.2% | 6,035,214 | SCHEDULE 13D/A, 2026-05-22 | 2026-05-20 |
| Marathon Asset Management Gp, L.L.C. | 6.8% | 2,710,229 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Hein Park Capital Management LP | 5.5% | 2,146,733 | SCHEDULE 13G, 2026-02-13 | 2025-12-31 |
| Hudson Bay Capital Management LP | 5.19% | 2,049,739 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
Purpose of Transaction (Item 4)
GoldenTree Asset Management LP
Endo Merger Pursuant to the transaction agreement (the "Transaction Agreement") between Endo, Inc. ("Endo") and Salvare Merger Sub LLC, a wholly owned subsidiary of the Issuer ("Merger Sub"), on July 31, 2025, Merger Sub merged with and into Endo (the "Merger"), with Endo surviving the Merger as a wholly owned subsidiary of the Issuer. As a result of the Merger, the Endo common stock held of record by certain managed accounts for which the Investment Manager serves as investment manager was cancelled and converted into the right to receive 4,539,148 Ordinary Shares. Additionally, affiliates of GoldenTree hold $11,000,000 of Endo Finance Holdings, Inc.'s 8.500% Senior Secured Notes due 2031; $147,092,630.42 of Endo Finance Holdings, Inc.'s Senior Secured Term Loan due 2031; $38,722,222.23 of MEH, Inc.'s Revolving Credit Facility due 2030; and $318,677,777.77 of MEH, Inc.'s Secured Term Loan due 2030. General The Reporting Persons acquired the securities described in this Schedule 13D for investment purposes and intend to review their investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons' review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and …The first part of Item 4 of the SCHEDULE 13D filed 2025-08-07; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-04 | Hein Park Capital Management LP | 4.9% | SCHEDULE 13D/A |
| 2025-08-07 | Hudson Bay Capital Management LP | 6.3% | SCHEDULE 13G/A |
| 2025-08-07 | GoldenTree Asset Management LP | 20.2% | SCHEDULE 13D |
| 2025-11-05 | Silver Point Capital, L.P. | 10.7% | SCHEDULE 13D/A |
| 2025-11-14 | Marathon Asset Management Gp, L.L.C. | 7.7% | SCHEDULE 13G/A |
| 2025-12-10 | Silver Point Capital, L.P. | 11.9% | SCHEDULE 13D/A |
| 2026-02-11 | Hudson Bay Capital Management LP | 5.19% | SCHEDULE 13G/A |
| 2026-02-13 | Hein Park Capital Management LP | 5.5% | SCHEDULE 13G |
| 2026-04-17 | Silver Point Capital, L.P. | 14.2% | SCHEDULE 13D/A |
| 2026-05-15 | Marathon Asset Management Gp, L.L.C. | 6.8% | SCHEDULE 13G/A |
| 2026-05-22 | Silver Point Capital, L.P. | 15.2% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Keenova Therapeutics plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.